ER-Positive HER2-Negative Breast Cancer
Conditions
Keywords
Metastatic, Breast Neoplasms, Neoplasms by Site, Neoplasms, Breast Diseases, Skin Diseases, Hormones, Hormone Substitutes, and Hormone, Physiological Effects of Drugs, Randomised, Multicentre, Double-Blind, Phase III, AZD9833, Next Generation Oral SERD, Anastrozole, Palbociclib, Antagonists, Antineoplastic Agents, Estrogen Receptor Antagonists, Hormone Antagonists, camizestrant
Brief summary
The study is intended to show superiority of AZD9833 in combination with palbociclib (a CDK4/6 inhibitor) versus anastrozole (an aromatase inhibitor) and palbociclib as the initial treatment of patients with hormone receptor-positive (ER-positive), human epidermal growth factor 2-negative (HER2-negative) advanced/metastatic breast cancer. INFORMATION FOR TRIAL PARTICIPANTS In this trial, the researchers will look at how well camizestrant with palbociclib works, compared with anastrozole with palbociclib, in participants with breast cancer that has either spread into other parts of the body at the time of diagnosis, or has come back after at least 2 years of standard endocrine treatment. Participants in this trial will have breast cancer that has ER proteins but does not have overexpression of HER2 protein.
Detailed description
A Randomised, Multicentre, Double-Blind, Phase III study will evaluate the safety and efficacy of AZD9833 (next generation oral SERD) in combination with palbociclib versus anastrozole in combination with palbociclib for the treatment of patients with ER-positive breast cancer. The goal of the study is to demonstrate superiority of AZD9833 over anastrozole in the context of combination with palbociclib in first line setting. INFORMATION FOR TRIAL PARTICIPANTS Researchers are looking for a better way to treat breast cancer. In people with cancer, some cells have grown out of control to form tumours. The trial drugs palbociclib, camizestrant, and anastrozole are designed to work by blocking the cancer's ability to grow. Camizestrant is also called AZD9833. Palbociclib and anastrozole are already available as treatments for people with certain type of breast cancer. In this trial, the researchers want to find out how well taking camizestrant with palbociclib, or anastrozole with palbociclib, works in participants with breast cancer that has ER proteins but does not have overexpression of HER2 protein. The researchers will look at which trial treatments help the participants live longer with cancer before it gets worse. The trial will split participants into 2 groups: * Participants in Group 1 will take camizestrant, palbociclib, and a placebo matched with anastrazole. * Participants in Group 2 will take anastrozole, palbociclib, , and a placebo matched with camizestrant. A placebo looks like a treatment but does not have any medicine in it. A computer program will be used to randomly choose the treatments each participant gets. This helps make sure the groups are chosen fairly. Researchers do this so that comparing the results of each treatment will be as accurate as possible. The participants will take their trial treatments in periods called cycles. Each cycle will last 28 days. During each cycle, the participants will take: * camizestrant or anastrozole once daily by mouth * palbociclib once daily by mouth for 21 days. Then, they will not take any palbociclib for 7 days Some participants will also get either goserelin or leuprorelin once every month. Participants could get goserelin or leuprorelin if: * They are medically determined yet to reach menopause status * They are male They will get this treatment as an injection under the skin or into a muscle. Goserelin and leuprorelin work by decreasing the amount of sex hormones made by the body which will lead to reduction of ER production. This can help stop breast cancer from growing. Participants will take trial treatment until the cancer gets worse or they leave the trial. Participants will visit their trial site several times throughout the trial. At these visits, the trial doctors will check the health of the participants. They will also take blood samples and do scans of the participants' tumors.
Interventions
DRUGAZD9833
Dosage formulation: AZD9833 tablets will be administered orally
DRUGAnastrozole
Dosage formulation: Anastrozole tablets will be administered orally.
Dosage formulation: anastrozole placebo tablets will be administrated orally.
DRUGAZD9833 placebo
Dosage formulation: AZD9833 placebo tablets will be administrated orally.
DRUGPalbociclib
Dosage formulation: palbociclib tablets/capsules will be administered orally
Men (when medically applicable) and pre- or peri-menopausal women are required to receive a monthly LHRH agonist.
Sponsors
AstraZeneca
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 130 Years
Healthy volunteers
No
Inclusion criteria
Full list of inclusion criteria * Pre-/peri-menopausal women or men can be enrolled if amenable to be treated with concomitant, approved LHRH agonists for the duration of the study treatment. * De novo Stage 4 disease, or recurrence from early stage disease after at least 24 months of standard adjuvant endocrine therapy. Note that at least 12 months must have elapsed since the patient's last dose of adjuvant AI therapy without disease progression on treatment. Note that a 2-week washout period is required after the last dose of tamoxifen prior to randomisation. * Histologically or cytologically documented diagnosis of ER+, HER2-negative breast cancer based on local laboratory results. * Previously untreated with any systemic anti-cancer therapy for their locoregionally recurrent or metastatic ER+ disease. * Measurable disease as defined per RECIST v.1.1 OR at least one lytic or mixed (lytic + sclerotic) bone lesion with a soft tissue component that can be assessed by CT or MRI. * Eastern Cooperative Oncology Group performance status of 0 or 1. * Adequate organ and marrow function. * Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. INFORMATION FOR TRIAL PARTICIPANTS Participants can join the trial if they: * Have breast cancer that cannot be treated with surgery or radiation * Have breast cancer that has already spread into other parts of the body at the time of diagnosis, or has come back after at least 2 years of a standard endocrine treatment * Have ER proteins but not overexpression of HER2 protein in their tumors * Have never received any type of cancer therapy that affects the whole body for advanced breast cancer * Are able to do their daily activities
Exclusion criteria
Full list of
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free survival (PFS) assessed by the Investigator as defined by response evaluation criteria in solid tumors (RECIST) version 1.1 | From randomization until progression per RECIST 1.1 as assessed by the investigator at local site or death due to any cause (up to 5 years) | PFS is defined as the time from randomization to objective disease progression (as assessed by RECIST) or death. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival (OS) | From randomization until the date of death due to any cause (up to 8 years) | The OS is defined as the time from randomization to death due to any cause. |
| Second progression-free survival (PFS2) | From randomization to the earliest of the progression event (following the initial progression), subsequent to first subsequent therapy or death (up to 5 years) | Time to second progression or death (PFS2) will be defined as the time from randomisation to the earliest of the progression event (following the initial progression), subsequent to first subsequent therapy or death. |
| Objective response rate (ORR) assessed by the Investigator as defined by RECIST version 1.1 | From randomization until a response or in the absence of a response from randomization up until progression, or the last evaluable assessment in the absence of progression (up to 5 years) | ORR is defined as the proportion of patients who have a CR or partial response, as determined by the investigator at local site per RECIST 1.1. |
| Time to chemotherapy (TTC) | From randomization until the earlier of the start date of chemotherapy or death due to any cause (up to 5 years) | Time to chemotherapy is defined as the time from randomization until the earlier of the start date of chemotherapy or death due to any cause. |
| Time to first subsequent anti-cancer therapy (TFST) | From randomization until the earlier of start date of the first subsequent anti-cancer therapy after discontinuation of randomized treatment, or death due to any cause (up to 5 years) | TFST is defined as time from randomization until the earlier of start date of the first subsequent anti-cancer therapy after discontinuation of randomized treatment, or death due to any cause. |
| Duration of response (DoR) assessed by the Investigator as defined by RECIST version 1.1 | From the date of first documented response until date of documented progression per RECIST 1.1 as assessed by the investigator at local site or death due to any cause (up to 5 years) | The DoR will be defined as the time from the date of first documented response until date of documented progression or death in the absence of disease progression. |
| Time to second subsequent therapy (TSST) | From randomization until the earlier of start date of the second subsequent anti-cancer therapy after discontinuation of first subsequent treatment, or death due to any cause (up to 5 years) | TSST is defined as time from randomization until the earlier of start date of the second subsequent anti-cancer therapy after discontinuation of first subsequent treatment, or death due to any cause. |
| Plasma concentration of AZD9833 at specified timepoints | on Day 15 | To assess the steady state PK of AZD9833 in combination with palbociclib in all participants who receive at least one dose of AZD9833 per the protocol, for whom there are at least one reportable PK concentration. |
| Change from baseline in EORTC QLQ-C30 scale scores | From baseline to 24 weeks post progression (up to approximately 5 years) | Change from baseline in EORTC QLQ-C30 scale scores for each patient at each post-baseline visit. The comparison will include all randomised patients, as randomised, with baseline and at least one post-baseline visit score for the scale score. |
| Change from baseline in EORTC QLQ-BR45 scale scores | From baseline to 24 weeks post progression (up to approximately 5 years) | Change from baseline in EORTC QLQ-BR45 scale scores for each patient at each post-baseline visit. The comparison will include all randomised patients, as randomised, with baseline and at least one post-baseline visit score for the scale score. |
| Clinical benefit rate at 24 weeks (CBR24) | At least 23 weeks after randomisation | CBR at 24 weeks is defined as the percentage of participants who have a complete response (CR) or partial response or who have stable disease (SD) per RECIST 1.1 as assessed by the investigator at local site for at least 23 weeks after randomization (to allow for an early assessment within the assessment window). |
Countries
Austria, Belgium, Bulgaria, Canada, Chile, China, Czechia, France, Germany, Hungary, India, Italy, Japan, Malaysia, Mexico, Norway, Poland, Portugal, Russia, Slovakia, South Korea, Spain, Switzerland, Taiwan, Turkey (Türkiye), United Kingdom, United States
Outcome results
None listed